Korona Patients Become Immune For At Least Six Months – NRK Urix – Foreign News And Documentaries



[ad_1]

This article is over a month old and may contain outdated advice from authorities regarding coronary heart disease.

Stay up to date on the NRK overview or on the FHI website.

A research group at the Rockefeller University in New York has examined the level of antibodies in the body of 87 patients who have suffered from the disease.

The group of patients was examined one month after illness and then again after six months.

After six months, the researchers found that the amount of antibodies in the blood had decreased, as several other studies have shown.

On the other hand, researchers believe that the memory cells of the immune system have become more powerful. Therefore, they are in a better position to produce antibodies that can attack the virus if they become infected again.

It is also believed that the body’s defenses can detect mutated versions of the virus.

– The main message is that the immune response persists, says Julio Lorenzi, one of the researchers behind the study.

Quality may be more important than quantity

Gunnveig Grødeland

QUALITY: Immunology researcher Gunnveig Grødeland says they have now started to ignore the amount of antibodies, but instead focus on the immune response.

Photo: Ola Sæther / UiO

The study has not yet been peer-reviewed or published in a scientific journal.

Immunology researcher at Oslo University Hospital Gunnveig Grødeland says there is a lot of research on the quality of antibodies that develop in coronary heart disease.

– An image has formed that the more seriously ill you have been, the higher the level of antibodies you have. But now they have started to look more at the quality of these antibodies and think that it may not be the levels that matter, but the quality of the immune response that is formed, Grødeland tells NRK.

– So even if you have had COVID-19 disease of a relatively moderate or mild degree, you may still have memory cells that can be activated and protect you from further infection. That’s good news.

And the fact that you still have memory cells in your body after six months may indicate that they stick around for a while.

Lifetime immunity?

Several candidate vaccines are now ready for approval. The effect of them varies between 70 and 95 percent, but nothing can yet be said about how long the immunity will last.

– It has not been studied whether those who have suffered the disease will have the effect of a vaccine. But if you already have responses by heart, a new exposure will increase their levels and the potential effect of them. They are trained to better recognize the virus, which should also help the protection last longer, says Grødeland.

In theory, vaccines can confer long-term, if not life-long, immunity to SARS-CoV-2. But viruses mutate. If it is a circulating coronavirus five years from now, it will probably be quite different from what we have now.

– We do not know to what extent the immune responses you get from the vaccine or infection will continue to protect against the mutated virus. But there is at least reason to believe that the memory cells it has formed will also be able to protect itself against future versions. The same possibly applies to antibodies that are formed against other parts of the coronary spine in addition to the tip where the virus attaches to host cells for infection. says Grødeland.

Much research remains

Anne-Marte Bakken Kran, chief physician in the department of infection control registries at FHI, says the new study is interesting and is in line with other findings in the field.

– There is also other data that indicates that the amount of antibodies decreases after a while, and you get more and better data on this now as time goes by and you can follow the first cases for a longer period of time, Kran tells him to NRK.

– One of the interesting things about this study is the findings they have made about a type of cell called memory B cells. These are cells that are reminiscent of the infectious substances the body is exposed to and ensure that it begins to produce antibodies quickly the next time it is exposed to the same microbe.

Much research is currently being done on the body’s ability to develop memory cells that can recognize and fight the virus.

– There is still a lot that you don’t know and more research is needed. But it is clear that knowledge of immunological memory is important to understand the development of the pandemic and also with regard to vaccination, says Kran.

She believes that time will tell if the body’s immune system and vaccination will eradicate the virus for good or if the immunity wears off over time.

– Now the virus has been circulating in much of the world for several months, and although some cases have been described in which someone has contracted the disease twice, not many have been mentioned. Therefore, most people will likely have an immunity that lasts for a few months after infection, but hopefully longer.

Several of the vaccines have been shown to give good immune responses, but to say anything about how long they last requires more observation time, Kran says.

AstraZeneca, University of Oxford

The corona vaccine developed at the University of Oxford prevents the symptoms of COVID-19 in 70 percent of cases.

The AZD1222 vaccine is based on the monkey ChAdOx1 virus. This virus is modified so that it cannot make copies of itself, so it does not cause disease. The researchers also changed the virus to carry additional information. The extra information causes your body to produce the so-called “spike protein” of the coronavirus.

What happens is the following: You get the vaccine in your body. The vaccine virus enters your cells. Inside cells, the production system discovers the additional information. Many copies of the “spike protein” are made. These copies are secreted by cells. Your immune system detects these proteins. An immune response is triggered. Antibodies against the coronavirus are produced and the immune system remembers that it is something to react to.

You have been vaccinated.

Biontech, Fosun Pharma and Pfizer

The German pharmaceutical company BioNTech reports that its coronary vaccine has been shown to be 95 percent effective.

The BNT162b2 vaccine relies on your body’s system for building things. The vaccine is just building instructions for the cells. The instructions are based on the same codes that cells use all the time for this purpose. These are called mRNAs or “messenger ribonucleic acids.”

What happens is the following:

The vaccine is injected into your body. The information from the vaccine reaches the machines in the cells that make proteins. These machines build copies of the so-called “spike protein” of the coronavirus. These proteins are secreted by cells and detected by the immune system. The immune system reacts in the same way as if the real coronavirus had entered the body. Antibodies are produced and the immune system remembers that the coronavirus is something foreign to react to.

You have been vaccinated.

Johnson and Johnson

The vaccine is in phase 3 of development.

Ad26 vaccine. COV2.S is based on the ad26 virus. It is a cold virus that circulates among humans. This is the virus that has been modified by researchers so that it cannot cause disease in humans. It also carries an extra gene, a bit of extra information. The extra information causes your body to produce the so-called “spike protein” of the coronavirus.

What happens is the following:

You get the vaccine in your body. The vaccine virus enters your cells. Inside cells, the production system discovers the additional information. Many copies of the “spike protein” are made. These copies are secreted by cells. Your immune system detects these proteins. An immune response is triggered. Antibodies against the coronavirus are produced and the immune system remembers that it is something to react to.

You have been vaccinated.

Novavax with partners

Novavax expects results in early 2021.

The NVX-CoV2373 vaccine is based on what are called nanoparticles. These are microscopic structures. The Novavax vaccine has nanoparticles that are primarily an extract from the Quillaja saponaria plant. This extract is used in much of the world as a food additive, but it also has medicinal properties. In addition, the vaccine particles are made up of cholesterol and fatty acids. The particles also carry the “spike protein” of the coronavirus. These nails are produced in genetically modified yeast cells and are added to the particles in the production process.

What happens is the following:

The vaccine works in two ways. Nanoparticles make your immune system respond better and spike proteins make the immune system react as if a real coronavirus has entered the body.

You have been vaccinated.

Modern

US Secretary of Health Alax Azar says the coronary vaccine at Pfizer and Moderna can be approved and distributed in a few weeks.

The mRNA-1273 vaccine relies on your body’s system to build things. The vaccine is just building instructions for the cells. The instructions are based on the same codes that cells use all the time for this purpose. These are called mRNAs or “messenger ribonucleic acids.”

What happens is the following:

The vaccine is injected into your body. The information from the vaccine reaches the machines in the cells that make proteins. These machines build copies of the so-called “spike protein” of the coronavirus. These proteins are secreted by cells and detected by the immune system. The immune system reacts in the same way as if the real coronavirus had entered the body. Antibodies are produced and the immune system remembers that the coronavirus is something foreign to react to.

You have been vaccinated.

In this phase, the vaccine is given to a small group of young, healthy people to see if the immune system responds. Researchers are also investigating whether it causes powerful and perhaps dangerous side effects. Also, based on the results, it is estimated how much vaccine should be administered.

In this phase, the vaccine is administered to a larger and wider group. The goal is to find variations in the response of the immune system and more data on side effects and the most reasonable amount of vaccine.

In this phase, it is investigated if the vaccine provides protection against the disease and if it causes more rare side effects. Several thousand people receive the vaccine and several thousand people receive a sham vaccine. Nobody knows who gets what. This is to ensure good scientific data.

The vaccine is ready for distribution.

The vaccine is approved for use in the EU and Norway.

[ad_2]